Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
The third major target is the selenoenzyme GPx4
Unlike most fat-derived hormones, adiponectin levels tend to decrease with an increase in body fat percentage in adults, linking lower adiponectin concentrations with obesity [27, 29]
For the best results, a series of treatments may be recommended, typically spaced a week or two apart
Retatrutide (LY3437943) is a synthetic peptide analog designed as a triple hormone receptor agonist, targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.[1][2] It has a molecular weight of approximately 4,800 Da and is administered subcutaneously, with a half-life supporting once-weekly dosing.[3][4] Developed by Eli Lilly, it is currently in Phase 3 clinical trials for obesity and type 2 diabetes (T2D), showing potential for superior weight loss compared to existing therapies.[1][5] Key characteristics for compounding pharmacies include: Multi-Receptor Agonist : Combines actions of GIP, GLP-1, and glucagon for enhanced metabolic effects.[1][6] Lyophilized Form : Supplied as a stable powder for reconstitution, similar to other peptides.[7][8] Versatile Delivery : Primarily subcutaneous, but potential for customized formulations in research contexts.[7][9] This makes Retatrutide a candidate for specialized preparations in compounding settings, though regulatory restrictions apply
Many users express frustration that dramatic transformations seen in animal studies don't translate to human experience
Experts now specify the following fiber targets for those on a GLP-1: 25 g/day of fiber for women, 30 g/day for men and 35 g/day for those with diabetes (Sievenpiper et al 2026) Healthy fats found in olive oil, nuts, seeds, avocado, fatty fish Hydration: 23 L/day for digestion, bowel health, kidneys and energy, up to 4 L/day depending in climate and activity
